Novo Nordisk partners with OpenAI for AI drug discovery

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorKavya Nair|Published at:
Novo Nordisk partners with OpenAI for AI drug discovery
Overview

Novo Nordisk is partnering with AI leader OpenAI to integrate advanced technology across its business. The deal covers drug discovery, manufacturing, and supply chains, aiming to boost efficiency and competitiveness in the fast-growing obesity drug market.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • ✓Quarterly Results
  • ✓Concall Announcements
  • ✓New Orders & Big Deals
  • ✓Capex Announcements
  • ✓Bulk Deals
  • ✦And much more
Add StocksGet it on Google PlayDownload on the App Store

AI Across the Business

Novo Nordisk is using artificial intelligence to transform its operations. The partnership with OpenAI will leverage AI's power to analyze large datasets, find new drug candidates, and make manufacturing more efficient. This also includes improving complex supply chains and commercial efforts.

The Obesity Drug Race

Novo Nordisk, maker of popular weight-loss drugs Wegovy and Ozempic, faces growing competition from rivals like Eli Lilly. Lilly recently won U.S. approval for its weight-loss pill Foundayo, intensifying the battle in a market expected to reach over $100 billion annually within ten years. Novo Nordisk aims to strengthen its position with new technology.

AI to Support Staff

Novo Nordisk CEO Mike Doustdar stated the collaboration's goal is to 'supercharge' its scientific teams, not replace them. AI integration aims to boost employee productivity and effectiveness, slowing future hiring instead of causing job cuts. OpenAI CEO Sam Altman noted AI's role in transforming industries and speeding up scientific discovery.

Rollout and Safety Measures

Pilot programs will begin in research, development, manufacturing, and commercial areas, with full integration planned by the end of 2026. Novo Nordisk confirmed the partnership includes strict data protection, governance rules, and human oversight, building on its existing AI projects.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Add Stocks
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.